Pemphigus Vulgaris (PV)

Also known as: Pemphigus Vulgaris / Pemphigus

DrugDrug NameDrug Description
DB00250DapsoneA sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
DB00073RituximabRituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences [A40017], [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
DrugDrug NamePhaseStatusCount
DB05516PI-08241Completed1
DB15312Orilanolimab1 / 2Recruiting1
DB00993Azathioprine2Completed1
DB01197Captopril2Terminated1
DB00531Cyclophosphamide2Terminated1
DB00250Dapsone2Terminated1
DB15270Efgartigimod alfa2Recruiting1
DB00005Etanercept2Completed1
DB00028Immune Globulin Human2Terminated1
DB05157KC7062Completed1
DB14867Parsaclisib2Withdrawn1
DB00635Prednisone2Completed1
DB00688Mycophenolate mofetil3Active Not Recruiting1
DB00688Mycophenolate mofetil3Completed1
DB06650Ofatumumab3Terminated1
DB00073Rituximab3Active Not Recruiting1